Dyadic Applied BioSolutions

Champions Of Affordable Recombinant Proteins and Enzymes

Joe paid his dues

It’s his time

Thanks for reading The Stock Pawnshop! Subscribe for free to receive new posts and support my work.

Ping Rawson’s helping

Monetized the enzymes

Changed the model

After a few

Recurring revenue now is in place

Profits come through….and will grow on, and on, and on, and on

We purchased Dyadic my friends

And we’ll support the stock ‘til the end

We bought the Dyadic

We bought the Dyadic

More growth for proteins

So we bought the Dyadic

Stock Pawnshop

We’ve taken some bows

On some of our calls

Holy Cross football player and an Iowa wrestler

They thank you all

Biomanufacturing’s had

No pleasure cruise

The Dapidus platform’s scalability is now in place

There’s not much to lose….so let us grow on, and on, and on, and on

We purchased Dyadic my friends

And we’ll support the stock ‘til the end

We bought the Dyadic

We bought the Dyadic

More growth for proteins

So we bought the Dyadic

Stock Pawnshop

We purchased Dyadic my friends

And we’ll support the stock ‘til the end

We bought the Dyadic

We bought the Dyadic

More growth for proteins

So we bought the Dyadic

Before deciding to put DYAI on the website, we shook our Magic 8 Ball and asked “Will subscribers make money on this dollarish stock?” the answer was MOST LIKELY. Gravy Train met with newly promoted Joe Hazelton this summer. He was impressed with Joe’s background in licensing and developing pharmaceuticals. Hence, the business model is much improved. Instead of earning revenue from outsourced R&D services, management pivoted to a more profitable commercial strategy. Three verticals being targeted are: life sciences, food & nutrition, and bioindustrial solutions.

The Stock Pawnshop listened to the 3rd quarter conference call on November 12th. Customers have placed purchase orders for Dapidus proteins. We are also impressed that the Gates Foundatioen provides milestone payments for DYAI’s C1-platform produced monoclonal antibodies. But we believe that more profits of this firm will be generated by proteins. Revenues should double in a couple of years as well as the business being cash flow positive.

If you want to do more work, the company’s redesigned website is a start and be on the look out for an investor conference webcast in early December.

Thanks for reading The Stock Pawnshop! Subscribe for free to receive new posts and support my work.